Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248651 · ClinicalTrials.gov registry record · Phase 2
Functional Dyspepsia Treatment Trial
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 292
- Enrollment target
NCT00248651: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00248651 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 292 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00248651, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 292 participants
- Enrollment target
Study Summary
Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea. These symptoms often interfere with school and work, and weight loss may occur due to dietary restrictions. The hypothesis of this study was that antidepressant therapy is more effective than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidity. The study also examined if antidepressant therapy reduces disability and improves quality of life in functional dyspepsia.
Interventions
- DRUG Placebo
- DRUG Escitalopram
- DRUG Amitriptyline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2006-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248651
The ClinicalTrials.gov registry entry for NCT00248651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00248651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00248651 about?
NCT00248651 is a clinical study titled "Functional Dyspepsia Treatment Trial". Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea. These symptoms often interfere with school and work, and weight loss may occur due to dietary restrictions. The hypothesis of this study wa...
What is the current status of trial NCT00248651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 292 participants. The study started on 2006-10. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00248651?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), Amitriptyline (DRUG).
Who is sponsoring clinical trial NCT00248651?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.